About: Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2002

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2002 (uk) im Jahr 2002 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2002 (ast) artikull shkencor i botuar më 01 janar 2002 (sq) scientific article published on 01 January 2002 (en)
publication date	wds:Q77645681-2C2D7547-63D7-4259-A38D-DC6CFC5418A3
publication date	2002-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q77645681-1C039F80-AE5E-4CA1-BC91-FDD846B60A9D wds:Q77645681-8DEA3224-E75D-406B-8C2A-A95B228D3956
author name string	Mike Greaves Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis
rdfs:label	Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (en) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (nl) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (sq)
skos:prefLabel	Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (en) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (nl) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (sq)
name	Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (en) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (nl) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie (sq)
title	wds:Q77645681-6915D74E-3234-4D9C-A1DC-4705197CEDB7
title	Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (en)
page(s)	wds:Q77645681-309C4E29-3674-4FF2-972A-068F5B3531C8
page(s)	163-164
instance of	wds:Q77645681-46E1F673-5487-4F42-8C7F-D66D03F5280E
instance of	scholarly article
main subject	wds:Q77645681-13E183D2-4D80-40A9-BAEC-C6B4FCCE6C27 wds:Q77645681-1CE0EA95-6A9F-4247-A1A5-53CDDA212B31 wds:Q77645681-335D60BC-E892-4B8F-95AC-5D67912168A2
main subject	thrombosis heparin anticoagulation
PubMed ID	wds:Q77645681-9D303492-3895-4AC0-9FC6-39D8D2B55434
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11848446
PubMed ID	11848446
published in	wds:Q77645681-49E1E8A4-7BD4-41CB-BDC1-B13AEA6F78D2
published in	Thrombosis and Haemostasis
issue	wds:Q77645681-EB7B1E5B-CD8F-45E5-AC9A-15A5B740695A
volume	wds:Q77645681-95AA546C-340B-45E7-98A1-059592FC7627
issue	1
volume	87
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q77645681
is cites work of	Anticoagulant therapy in pediatrics Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments Clinical review: Patency of the circuit in continuous renal replacement therapy Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Renal replacement therapy in acute kidney injury: controversy and consensus What are the anticoagulation options for intermittent hemodialysis? Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. Toward development of a point-of-care assay of enoxaparin anticoagulant activity in whole blood
is cites work of	wds:Q26829750-E815F2C1-07C5-465B-BBE9-DBCC9E854118 wds:Q33399961-07EBF50B-2407-412B-AB32-7DD3C36DF6A5 wds:Q55337905-EE3CBAB9-377C-4DB7-AF20-5CB3D8B558B9 wds:Q33396089-82BB9E3C-9585-4275-AEFA-0345C3AA0127 wds:Q33375906-CCF0967B-50A2-4950-94DC-C801ECA8E1C6 wds:Q55455218-B8E27CDF-E95C-4427-AF5A-9F3075E39B89 wds:Q26998864-17540F11-3B11-4631-B1C5-71B855579455 wds:Q36384559-BD641D36-1055-4FCB-980C-5B3AA09D764B wds:Q37406823-08E43BBF-15A5-4A71-BE1B-8FC9F81DBC94 wds:Q36510063-5D6B21E2-47EA-4F81-B469-890FABBF45BC wds:Q35549780-228A5A25-220C-4FA7-AEE7-886C1063B3F9 wds:Q83147195-09D8D1A5-7FDA-4EE1-B090-EFD29D19239A

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software